GlassScriptPhysician profile
Maria Torres
NPI 1790541324
$6,443.02
in general payments reported to CMS, 2019-2025
32 companies · $4,029 in 2025
The $4,029 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,414 · 2025: $4,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,443.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.43 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $804.21 | 2024-2025 | Ingrezza |
| Pfizer INC. | $568.36 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $482.49 | 2024-2025 | Nuplazid |
| Lilly USA, LLC | $465.36 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Amneal Pharmaceuticals LLC | $406.21 | 2024-2025 | Crexont, Rytary, Ongentys |
| Eisai INC. | $336.25 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $329.04 | 2024-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $238.10 | 2024-2025 | Leqembi, Skyclarys |
| Lundbeck LLC | $213.43 | 2024-2025 | Vyepti |
| Ucb, INC. | $210.13 | 2024-2025 | Rystiggo, Nayzilam |
| Merz Pharmaceuticals, LLC | $194.48 | 2024-2025 | Xeomin, Inbrija |
| Takeda Pharmaceuticals U.S.A., INC. | $104.90 | 2024-2025 | Hyqvia |
| Ge Healthcare | $74.78 | 2025 | |
| Mdd US Operations, LLC | $72.77 | 2024-2025 | Gocovri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $63.81 | 2025 | Radicava |
| Impel Pharmaceuticals LLC | $57.19 | 2025 | Trudhesa |
| Revance Therapeutics, INC. | $55.53 | 2024-2025 | Daxxify |
| Supernus Pharmaceuticals, INC. | $51.83 | 2025 | Qelbree |
| Microtransponder, INC. | $43.13 | 2025 | |
| C2n Diagnostics, LLC | $42.19 | 2025 | Precivityad2 |
| Kyowa Kirin, INC. | $41.98 | 2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $41.68 | 2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $36.77 | 2024 | |
| Acorda Therapeutics, INC | $34.25 | 2024 | Inbrija |
| Axsome Therapeutics, INC. | $29.87 | 2025 | Symbravo |
| Csl Behring | $29.83 | 2024 | Hizentra |
| Genentech USA, INC. | $28.31 | 2024 | Evrysdi |
| Alexion Pharmaceuticals, INC. | $27.18 | 2024 | Ultomiris |
| Medtronic, INC. | $24.41 | 2025 | Percept PC Brainsense |
| Grifols USA, LLC | $23.09 | 2024 | Gamunex-C |
| Amgen INC. | $23.03 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.